We demonstrated active TF in 14.7% of patients on admission, and in 21% after 24 h—fractions lower than in our previous report, where active TF measured after 72 h since AIS onset was detectable in 33.1% of patients [25]. This evidence concerns the gene TF and androgen insensitivity syndrome.